Related Experiment Video

Updated: Jul 20, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2

Aaron B Coleman1

  • 1Division of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. acoleman@coh.org

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|May 6, 2003
PubMed

Insights

Fibroblast growth factor-2 (FGF-2) influences cancer drug effectiveness, causing both resistance and sensitization. Understanding FGF-2

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Drug Resistance Mechanisms

Background:

  • Tumor cell resistance to chemotherapy is a major obstacle in cancer treatment.
  • Fibroblast growth factor-2 (FGF-2) is recognized for its role in modulating cellular sensitivity to anti-cancer drugs.

Purpose of the Study:

  • To investigate the dual role of FGF-2 in mediating both drug resistance and sensitization in cancer cells.
  • To explore how differential cellular trafficking and biological activities of FGF-2 isoforms impact chemotherapy outcomes.
  • To determine the clinical implications of manipulating FGF-2 activity to enhance chemotherapeutic efficacy.

Main Methods:

  • Analysis of FGF-2 isoforms' cellular localization and biological functions.
  • Evaluation of FGF-2's effect on normal and tumor cell sensitivity to various cytotoxic agents.
  • Investigation of FGF-2 expression in tumor cells and its correlation with chemotherapy response in vivo.

Main Results:

  • FGF-2 exhibits a dual effect, inducing both resistance and sensitization to chemotherapy depending on the cell type and agent used.
  • Differential trafficking and activities of FGF-2 isoforms contribute to its varied effects on drug action.
  • Elevated FGF-2 expression in tumors is associated with a reduced response to chemotherapy.

Conclusions:

  • FGF-2 plays a complex role in cancer chemotherapy, influencing treatment outcomes.
  • Targeting FGF-2 pathways may offer a strategy to overcome chemotherapy resistance and improve treatment effectiveness.
  • Further research into FGF-2 isoforms is crucial for developing novel therapeutic approaches in oncology.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...